Kornimate/medical-research-clean huggingface dataset:
generation of lung tumor organoids from patients undergoing diagnostic bronchoscopy

Conditions: Generation of Lung Cancer Organoids

Summary: interventional (low intervention level), non-pharmacological, prospective, feasibility pilot study of the preparation of organoids starting from lung tumor tissue collected during biopsies performed via diagnostic bronchoscopy according to standard clinical practice.

interventional, non-pharmacological, prospective, feasibility pilot study of the preparation of organoids starting from lung tumor tissue collected during biopsies performed via diagnostic bronchoscopy according to standard clinical practice. this protocol is classified as "interventional" (low intervention level) since that, if possible, an additional quantity of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids. involves the prospective recruitment of patients undergoing diagnostic bronchoscopies for suspected lung cancer.

Eligibility criteria:
inclusion criteria: * patients with suspected diagnosis of centrally located and accessible lung cancer endoscopically; * patients for whom it is indicated to undergo in-depth diagnostic testing through bronchoscopy for the purpose of determining the histotype of the lung neoplasm, according to clinical practice standard; * aged over 18; * patients who express informed consent to the study. exclusion criteria: * medical contraindication to taking biopsy samples; * medical contraindication to carrying out endoscopic investigations; * patients with suspected lung cancer not accessible endoscopically; * patients with lung neoformation already subjected to diagnostic sampling; * contraindications to taking an additional quantity of tissue.

Keywords: organoids.
observational study to monitor long-term immunogenicity and efficacy of ub 311 vaccine in subjects with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this observational study is to determine whether the vaccine (ub 311), targeting the n-terminal amino acids (1-14) of the amyloid beta peptide, has long-term immunogenicity and efficacy in individuals diagnosed with mild or moderate alzheimer's disease (ad) who previously received ub 311-treatment. amyloid beta was selected as the target antigen based on supporting evidence of the hypothesis that places the accumulation of amyloid beta at the initiating step of ad.


Eligibility criteria:
inclusion criteria: * individuals with mild to moderate alzheimer's disease who received three (3) injections of ub 311 in the initial phase i v118-ad trial exclusion criteria: * individuals with alzheimer's disease who are currently on prohibited medications, have severe or uncontrolled systemic disease, or are unable or unwilling to comply with study protocol requirements.

Keywords: alzheimer's disease amyloid beta vaccine
diagnosing drug allergy: the t is the key

Conditions: Amoxicillin Allergy

Summary: the goal of this clinical trial is to validate a newly developed test in the diagnosis of patients with amoxicillin allergy (i.e. t-cell activation test). the main questions the study aims to assess are the reliability and applicability of this test. participants will be asked to visit the hospital 1, 3 or 5 times during which blood is collected and when applicable, allergy skin testing is performed.

drug allergy is a significant health issue with a serious medical and financial burden of mis- and overdiagnosis. currently applied tests differ for immediate and nonimmediate drug allergy and have variable sensitivity and specificity. therefore, correct diagnosis remains difficult and frequently requires potentially dangerous and time-consuming challenge tests. drug-specific t-cells play a central role in initiation and maintenance of both immediate and nonimmediate drug allergy and can be studied in the lymphocyte transformation test (ltt). however, technical difficulties have hindered entrance of the ltt in mainstream use. the investigators' data indicates that flow-based intracellular trapping and staining of markers induced during activation (such as cd154 and cytokines) enables a rapid enumeration of rare drug-specific t-cells in the blood of patients with immediate and nonimmediate amoxicillin allergy. the ambition of this project is to validate a "one fits all" assay that meets the requirements of a safe, patient friendly, accessible, and performant test that could merits the status of a primary investigation in the diagnostic algorithms. moreover, as the tests is cost effective, it could also become an attractive method for broader applications such as the delabelling of spurious allergies. this project will focus on allergy to amoxicillin.

Eligibility criteria:
inclusion criteria: participants are eligible if they: * are ≥ 6 years * are capable of informed consent, or if appropriate, participants have an acceptable individual capable of giving consent on the participant's behalf (e.g. parent or guardian of a child under 18 years of age) * have a suspected history of amoxicillin allergy exclusion criteria: * patients who are lacking capacity or do not have an acceptable individual capable to provide informed consent * pregnant women * breastfeeding women

Keywords: amoxicillin amoxicillin allergy allergy t-cells
endometrial assessment of women with uterine infection

Conditions: Infertility

Summary: unexplained infertility is clinically diagnosed when there are no apparent or clear factors causing infertility on regular infertility assessment tools . failure of implantation is a possible factor causing unexplained infertility .

implantation is the main rate limiting step in ivf outcome. implantation is described at the cellular and the molecular levels by adhesion or fixation of a good quality embryo to receptive endometrium within a critical period of time, which is called the window of implantation

Eligibility criteria:
inclusion criteria: * women with infertility age from 20-40 years exclusion criteria: * any factor of infertility
online self-care training program (mago study)

Conditions: Occupational Burnout

Summary: this study aims to determine the efficacy of mago (online self-care training program for psychologists), a person-directed, individual, occupational intervention via videoconference in six sessions on a weekly basis. by promoting self-care behaviors, it is expected to reduce burnout levels and to increase work engagement in clinical psychologists working in chile.

clinical psychologists are susceptible to develop burnout as a result of facing consistently emotionally taxing job demands and a high requirement for empathy. implementing self-care behaviors can help to prevent negative consequences of work stress and the promotion of positive outcomes such as optimal professional functioning and enhanced well-being in psychologists. the intervention is a person-directed, individual, primary occupational intervention. it will be carried out via videoconference in six weekly sessions of 45 minutes. mago is a program derived from self-care assessment for psychology (scap). from a preventive perspective on self-care, items represent strategies or behaviors that may be integrated into one's professional and personal life on a more ongoing and proactive basis to promote well-functioning. chile has presented a slow but progressive development of e-mental health research, and internet-based interventions are at an early stage of development in this country. using videoconference and web-delivered questionnaires are crucial in reaching psychologists considering problems such as long distances of transportation and a tiny budget for mental health. nevertheless, chile scores 52 in the global connectivity index, while digital technologies are highly utilized across all social strata.

Eligibility criteria:
inclusion criteria: * chilean psychologists * currently working in the public sector in chile * available to attend to six online sessions * willing to voluntarily participate exclusion criteria: * subjects participating in psychotherapy as clients * high scores for depression or anxiety

Keywords: burnout self-care online program telepsychology
safety, efficacy, and feasibility of high-dose cholecalciferol in pediatric patients with cystic fibrosis

Conditions: Vitamin D Deficiency

Summary: children with cystic fibrosis, ages greater than and equal to 36 months of age and less than or equal to 18 years of age, with a 25ohd level less than 30 ng/dl will be asked to participate in this study. upon consent, they will be given oral cholecalciferol supplementation of 250,000 iu during their next cf clinic visit. the safety will be assessed by measuring a serum calcium level within 1 week of supplementation. efficacy will be assessed using repeated 25ohd levels throughout the course of 12 months. feasibility will be assessed with the previous two measures as well as a brief questionnaire administered via telephone within 1 week of supplementation.

children and adults with cystic fibrosis (cf) are at risk of developing a vitamin d deficiency or insufficiency, defined as a 2,25-hydroxyvitamin d (25ohd) serum blood level \<30 ng/dl. greater than 85% of people with cf have pancreatic insufficiency, which contributes to poor absorption of fat soluble vitamins in addition to dietary fat. a 25ohd level greater than 30 ng/dl has been described as providing potential improvements to markers of inflammation in adults with cf and is known to improve bone mineral density and prevent bone fractures in all populations, including cf. this study will assess the safety of a one-time high dose of cholecalciferol or vitamin d3 along with the efficacy and feasibility. children between the ages of 3 years and 18 years (inclusive), with a 25ohd level \<30 ng/dl will be provided with a vitamin d3 supplement of 250,000 international units (iu) observed in our cf clinic. we hypothesize that this one-time, oral, high dose of vitamin d3 will safely and effectively raise the 25ohd level to above 30 ng/dl. safety will be monitored with serum calcium levels 1 week following the dosage, since 25ohd has a half-life of 2-3 weeks and this serum calcium level measurement time-point would be in or near the middle of this range. feasibility will be measured using a 5-question phone survey 1 week following the dosage (see appendix a - attached). efficacy will be measured by the 25ohd level itself; if 25ohd levels are found to be between 30-100 ng/dl over the course of the study, the dose will have demonstrated effective in achieving the study's goal. the purpose of this study is to show that 25ohd levels can be safely corrected with a one-time dose of vitamin d3 that can be safely and feasibly provided in the outpatient setting to children with cf.

Eligibility criteria:
inclusion criteria: * children with cystic fibrosis \>36 months of age * serum/blood 25ohd level \< 30 ng/dl * ability to provide valid informed consent to be a part of the study exclusion criteria: * any history of kidney disease, kidney stones or on dialysis * any history of hypercalcemia * any history of hypercalciuria * pregnancy at time of enrollment * any history of parathyroid disorders * inability to swallow pills by mouth
repositionable versus balloon-expandable prosthesis for trans-catheter aortic valve implantation

Conditions: Aortic Valve Disease

Summary: there are different aortic valve prosthesis used for treatment of aortic valve disease through catheter-based procedures. the current study aims to compare two different aortic valve prosthesis regarding their outcomes at 30-day and 2-year follow-up.

important improvements in aortic valve prostheses technology has been made aiming comparable performance of these prosthesis to surgical valve ones. the experience with the early generation of aortic valve prostheses revealed some important differences regarding the incidence of paravalvular leakage, need for pacemaker or valve thrombosis among them. currently the new generations of valve prostheses such as sapien 3 balloon-expandable valve and lotus, repositionable valve are the most frequently used devices. there are registry data about the clinical performance of these valve types but a randomized comparison is missing.

Eligibility criteria:
inclusion criteria: 1. symptomatic aortic valve disease in need of valve replacement 2. heart team (including at least a cardiac surgeon and an interventional cardiologist) agrees on the eligibility that trans-femoral tavi is appropriate. 3. study patient is an adult of legal consent age. 4. study patient has provided written informed consent to participate in the study exclusion criteria: 1. life expectancy \< 12 months due to co-morbid conditions. 2. native aortic valve annulus size and morphology not suitable for lotus or sapien prosthesis implantation 3. preexisting bioprosthetic valve or ring in aortic valve position. 4. pre-existing pacemaker or icd/crt. 5. cardiogenic shock or hemodynamic instability. 6. history of active endocarditis 7. contraindications for a trans-femoral access. 8. severe left ventricular dysfunction with lvef \<30%. 9. severe mitral valve insufficiency. 10. echocardiographic evidence of intracardiac mass, thrombus or vegetation. 11. patients actively participating in another drug or device investigational study and have not yet completed the primary endpoint follow-up period. 12. patients suffering from dementia. 13. pregnant or nursing women

Keywords: tavi trans-femoral sapien lotus
fractional erbium yag laser vs intradermal and systemic tranexamic acid

Conditions: Refractory Melasma

Summary: melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes. melasma is a name derived from the greek word melas meaning black.it is characterized by the appearance of brownish or grayish symmetrical patches on sun-exposed skin, most commonly on the face. compared to men, women are more likely to be affected.

melasma is more common in people with dark complexions and fitzpatrick skin types iii iv.depending on ethnicity and region, melasma prevalence might vary from 8.8% to 40%. the cause of melasma is still unknown in the meantime. numerous elements, including genetics, sunshine, endocrine stimulation, oxidative conditions,pregnancy, exogenous hormons,and morphofunctional changes, may have a role in the development of the disease. since melasma is a common skin condition affecting mostly pregnant women and those on hormonal birth control, it is known as the "mask of pregnancy, treatment for melasma remains a challenge, with substantial psychosocial ramifications. many factors, including variability in clinical presentation and responsiveness to treatment between genders, skin phototypes, and ethnicities, can affect treatment efficacy. none of variety methods have been sufficiently effective to be considered the gold standard. hydroquinone (hq) has historically been the most studied topical agent in the treatment of melasma. hq is a hydroxyphenolic compound that inhibits the conversion of dopa to melanin by the inhibition of tyrosinase; it also inhibits rna and dna synthesis of melanocytes and degrades melanosomes. tranexamic acid (txa) is an antifibrinolytic drug that has been used off-label for the treatment of melasma, as an oral or intradermal injection. txa is a lysine-derived amino acid with anti-inflammatory effects that prevents ultraviolet (uv)-induced skin pigmentation by inhibiting attachment of plasminogen to keratinocytes and activation of plasmin. plasmin stimulates melanogenesis by conversionof arachidonic acid to prostaglandin and leukotriene. on the other hand, plasmin increases the level of melanogenic factors. laser therapy is a unique ablative modality that might potentially increase the penetration of medications applied topically by destroying the sc, epidermal, and dermal layers of the skin in a predictable and controlled manner. the fractional erbiumdoped yttrium aluminum garnet (er: yag) laser has a wavelength of 2,940 nm and is strongly absorbed by water in the epidermis. it exerts its ablation effect with minimal penetration depth and minimal heat generation and therefore minimal thermal damage.

Eligibility criteria:
inclusion criteria: - patients of both sexes with melasma. exclusion criteria: * pregnancy * lactation * administration of oral contraceptive pills or any phototoxic drug within 1 month prior to study * patients with a history of thrombosis, abnormal bleeding profile, known hypersensitivity to ta or hq, and endocrinal disease.
modified cervical inversion during cs in placenta previa

Conditions: Placenta Previa

Summary: there is an increasing rates of placenta previa nowadays

several techniques were described to control bleeding .

Eligibility criteria:
inclusion criteria: * pregnant women 38 weeks or more with placenta previa exclusion criteria: * pregnant ladies with normally implanted placenta or placenta accreat , increta or percreta
magnesium sulfate for tap analgesia during laparoscopic cholecystectomy

Conditions: Postoperative Pain

Summary: study the effect of adding magnesium sulfate to tap block in analgesia after laparoscopic cholecystectomy.

after approval of local ethical committee, consent will be obtained from 90 patients scheduled for laparoscopic cholecystectomy in gec center, mansoura university, egypt. patients will be of either asa i and ii, with age ranging from 18-40 years, and bmi less than 35. patients will be randomized into 3 groups (using closed envelope technique in blocks of 18); controlled group (c group), bupivacaine group (b group), bupivacaine magnesium group (m group). anesthesia induction will be the same in the three groups (propofol 1-1.5mglkg, fentanyl 1 mic/kg, atracrium 0.5 mg/kg) then sevoflorane inhalational anesthesia for maintainace in 0.4 oxygen/air mixtures. in both m group and b group, preemptive us guided subcostal tap block (toshiba xario, japan) was performed on both sides using 20 ml volume (0.25 bupivacaine in b group or 0.25 bupivacaine plus 0.5 gm mgso4 in m group). surgical sterilization will be started 5 minutes after the block and surgery started5 minutes later. hemodynamic data (hr, map) will be collected immediately after induction, at start of surgery, and each 10 minutes later. at the end of surgery, and after closure of surgical ports, anesthesia was terminated and extubation done when patients fulfilled the required criteria. postoperative hemodynamic data (hr, map), vas, and ponv will berecorded at 0, 1, 2, 6, 12, 24 hours after surgery, ramsay sedation was recorded at 0, 1, 2, 6 hours postoperatively. boluses of morphine (0.02 mg/kg) will be given whenever vas ≥4.

Eligibility criteria:
inclusion criteria: * asa i, ii for lap cholecystectomy exclusion criteria: * asa iii, iv
evaluation of a free-breathing cardiac cine-mri sequence with image reconstructions by deep-learning in ischemic heart disease

Conditions: Magnetic Resonance Imaging; Cardiac Magnetic Resonance Imaging; Deep-Learning; Left Ventricular Ejection Fraction

Summary: today, mri is the gold standard for the precise assessment of left ventricular volume and function, but presents the drawback of having a long acquisition time and of generating motion artifacts, in particular respiratory artifacts, requiring repeated sequences in apnea to cover the whole cardiac volume. these apneas are difficult to achieve in patients with ischemic heart disease and may lead to degradation of the images, an increase in the duration of the examination by repeated acquisitions and therefore to diagnostic inaccuracies. artificial intelligence, already used in practice in cardiac mri for automatic segmentation of the heart chambers, improves radiological interpretation with rapid and precise measurements. deep-learning, which is part of artificial intelligence, would allow the reconstruction of cine-mri sequences in free breathing, in order to overcome the artifacts from respiratory motions, and the improvement of diagnostic performance while improving examination conditions for patients. patients coming for a cardiac mri for the assessment of ischemic heart disease will be eligible to the protocol. if the patient agrees to participate, a free-breathing cardiac cine-mri sequence with deep learning based image reconstruction will be added to the usual protocol. no follow-up will be required in this study.


Eligibility criteria:
inclusion criteria: * age \> or = 18 years old * ischemic heart disease * ability of the subject to understand and express his consent * affiliation to the social security scheme exclusion criteria: * major obesity (\> 140kg) not allowing the patient to enter the tunnel of the machine whose diameter is less than 70cm * under 18 years old * pregnant woman * known allergy to gadolinium chelates * claustrophobia * any contraindication to mri * arrhythmia * difficulty in holding apneas of more than 10 seconds

Keywords: magnetic resonance imaging cardiac magnetic resonance imaging deep-learning left ventricular ejection fraction left ventricular end systolic volume left ventricular end diastolic volume
prospective memory imaging

Conditions: Alzheimer Disease

Summary: the purpose of this study is to investigate prospective merory (memory of intentions) in healthy controls and in amci (amnestic mild cognitive impairment) and ad (alzheimer disease) patients.


Eligibility criteria:
inclusion criteria : * education level \> 7 years * native language: french * beck \< 7 * medical, neurological, neuropsychological and neuroradiological depth in accordance with the criteria for inclusion and exclusion-specific population, that is to say: * young healthy subjects: between 18 and 44 years old; * middle age healthy subjects: between 45 and 69 years old; without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery. * elderly healthy subjects: over 70 years old, without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery. * mci patients: over 50 years old, presenting the current criteria for amnestic mci including: i) memory complaint, ii) deficits of the episodic memory (lower performance of at least 1 sd from the norm for age and cultural level for one or more scores of episodic memory and iii) normal performances compared to the age and the educational level of all other cognitive functions as memory, including tests to assess cognitive abilities. * alzheimer's patients: over 50 years old, presenting the standard criteria of nincds-adrda probable alzheimer's disease, including abnormal global cognitive function and deficits in at least two cognitive domains identified by the diagnostic battery and a mild to moderate alzheimer's disease (mmse ≥ 18). exclusion criteria : * the sudden onset of cognitive impairments (as opposed to their slow and gradual installation in alzheimer's disease) * a chronic neurological, psychiatric, endocrine, hepatic or infectious complaint * a history of major disease (a lung, heart, metabolic, hematologic, endocrine disease or a severe cancer); * a medication that may interfere with memory or metabolic measures * a alcohol or drugs abuse * claustrophobia, metallic object in the body * a predominantly left-hand (score below 50% in edinburgh inventory). * protected adults, and persons not affiliated with a social security system will not participate in this study. * pregnant or suckling women * the inclusion of a participant in another biomedical research protocol (during the study or within 12 months before inclusion)

Keywords: prospective memory healthy aging alzheimer disease brain imaging